146 related articles for article (PubMed ID: 19960343)
41. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Liu L; Zhou F; Ren S; Chen X; Li X; Li W; Zhou C
Asia Pac J Clin Oncol; 2016 Jun; 12(2):e339-46. PubMed ID: 25131817
[TBL] [Abstract][Full Text] [Related]
43. Prognostic Impact of DNA Repair Protein Expression in Non-Small Cell Lung Cancers Treated with Platinum-Based Chemotherapy and Subsequent Curative Lung Resection.
Shin J; Lee KS; Yoh KA; Cho HJ; Choi MK; Kim SH; Kim YJ; Chung JH; Cho S; Kim K; Jheon S; Yoon HI; Lee JH; Lee CT; Lee JS
Oncology; 2018; 95(1):20-30. PubMed ID: 29694959
[TBL] [Abstract][Full Text] [Related]
44. Non-platinum combination of gemcitabine in NSCLC.
Favaretto AG
Ann Oncol; 2006 May; 17 Suppl 5():v82-5. PubMed ID: 16807471
[No Abstract] [Full Text] [Related]
45. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
[TBL] [Abstract][Full Text] [Related]
46. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
[TBL] [Abstract][Full Text] [Related]
47. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
[TBL] [Abstract][Full Text] [Related]
48. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Santarpia M; Ramirez JL; de Aguirre I; Garrido P; Pérez Cano M; Queralt C; Gonzalez-Larriba JL; Insa A; Provencio M; Isla D; Camps C; Blanco R; Moran T; Rosell R;
Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619
[TBL] [Abstract][Full Text] [Related]
49. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
Xu XL; Zhang YP; Fang Y; Su D; Chen W; Feng JG; Li ZP; Mao WM
J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C49-55. PubMed ID: 26323924
[TBL] [Abstract][Full Text] [Related]
50. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
Yu Y; Xu X; Du Z; Shi M
Cancer Chemother Pharmacol; 2012 May; 69(5):1265-75. PubMed ID: 22297708
[TBL] [Abstract][Full Text] [Related]
51. Polymorphisms of the XRCC3 C722T and the RAD51 G135C genes and the risk of head and neck cancer in a Polish population.
Sliwinski T; Walczak A; Przybylowska K; Rusin P; Pietruszewska W; Zielinska-Blizniewska H; Olszewski J; Morawiec-Sztandera A; Jendrzejczyk S; Mlynarski W; Majsterek I
Exp Mol Pathol; 2010 Dec; 89(3):358-66. PubMed ID: 20804747
[TBL] [Abstract][Full Text] [Related]
52. Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Chen X; Zhang L; Ren S; Li X; Zhou F; Li W; Gao G; He Y; Zhou C
Med Oncol; 2014 Apr; 31(4):865. PubMed ID: 24535606
[TBL] [Abstract][Full Text] [Related]
53. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
[TBL] [Abstract][Full Text] [Related]
54. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
Adjei AA; Salavaggione OE; Mandrekar SJ; Dy GK; Ziegler KL; Endo C; Molina JR; Schild SE; Adjei AA
J Thorac Oncol; 2010 Sep; 5(9):1346-53. PubMed ID: 20651609
[TBL] [Abstract][Full Text] [Related]
55. DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
Erčulj N; Kovač V; Hmeljak J; Franko A; Dodič-Fikfak M; Dolžan V
J Thorac Oncol; 2012 Oct; 7(10):1609-17. PubMed ID: 22982660
[TBL] [Abstract][Full Text] [Related]
56. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
[TBL] [Abstract][Full Text] [Related]
57. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Nie X; Cheng G; Ai B; Zhang S
Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
[TBL] [Abstract][Full Text] [Related]
58. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Li XD; Han JC; Zhang YJ; Li HB; Wu XY
Asian Pac J Cancer Prev; 2013; 14(1):145-8. PubMed ID: 23534713
[TBL] [Abstract][Full Text] [Related]
59. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
60. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Feng J; Sun X; Sun N; Qin S; Li F; Cheng H; Chen B; Cao Y; Ma J; Cheng L; Lu Z; Ji J; Zhou Y
Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):429-35. PubMed ID: 19430706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
